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INTRODUCTION 
Cardiorenal syndromes (CRS) are defined as disorders of the 
heart and kidney in which acute or chronic dysfunction in one organ 
may induce acute or chronic dysfunction in another organ1. Of the 
five types of CRS, type 1 CRS is characterized by acute kidney 
injury (AKI) due to rapid worsening of cardiac function. Indeed, AKI 
often develops in patients with acute myocardial infarction (MI) and 
is strongly associated with mortality in patients with MI. Decreased 
renal blood flow due to cardiac dysfunction and elevated renal 
venous congestion have been suggested to induce type 1 CRS 
through activation of the sympathetic nervous system and renin-
angiotensin-aldosterone (RAA) system2. In addition, non-
hemodynamic mechanisms such as increased oxidative stress and 
chronic inflammation contribute to type 1 CRS3. Diabetes mellitus 
(DM) is an independent risk factor for the development of AKI in 
patients with MI4-6, and we recently reported that augmented 
activation of toll-like receptors (TLRs), germline-encoded innate 
immune receptors7, plays roles in the susceptibility to AKI after MI 
in DM rats8. However, how pharmacological treatment of 
hyperglycemia modifies the DM-induced increase in renal 
susceptibility to AKI remains unclear. 
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are newly 
developed glucose-lowering agents that inhibit glucose reuptake 
at the renal proximal tubule where most of the glucose is 
reabsorbed. Recent clinical trials have demonstrated that 
treatment with an SGLT2 inhibitor significantly reduced not only 
cardiovascular events but also renal events including decreases in 
estimated glomerular filtration rate (eGFR), progression of 
albuminuria and onset of renal replacement therapy9,10. 
Amelioration of renal hyperfiltration, high glucose-induced increase 
in oxidative stress, inflammation and apoptosis are possible 
mechanisms of protection by SGLT2 inhibitors11. Indeed, an 
SGLT2 inhibitor suppressed oxidative stress and inflammation in 
the kidneys of animal models12-14. Interestingly, it has been 
reported that SGLT2 inhibitors increase the circulating level of β-
hydroxybutyrate (βOHB), a ketone body15,16, and that βOHB 
attenuates oxidative stress by upregulating anti-oxidative 
molecules via inhibition of histone deacetylases (HDACs)17. On the 
other hand, the initial dip in eGFR by SGLT2 inhibitors treatment 
may increase the risk for AKI18, though there is no evidence to 
support such a possibility. The effects of SGLT2 inhibitors on CRS 
in DM have not been specifically examined. 
In the present study, we examined the effect of canagliflozin, an 
SGLT2 inhibitor, on the increased susceptibility to AKI after MI in 
DM. As a model of DM, we used Otsuka Long-Evans Tokushima 
Fatty rats (OLETF) at ages of 25-30 weeks. The reason for 
selection of OLETF in this study is three-fold. First, OLETF 
spontaneously develop DM primarily by hyperphagia due to a lack 
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of cholecystokinin-A receptor in the brain and they show the typical 
phenotype of type 2 DM (i.e., obesity, hyperinsulinemia and 
hypertriglyceridemia)19,20. Second, OLETF at the ages of 25-30 
weeks show an early stage of diabetic nephropathy: lower serum 
creatinine level with protein urea than that in Long-Evans 
Tokushima Otsuka rats (LETO), non-DM control rats8,21,22. Third, 
we previously found that renal susceptibility to type 1 CRS was 
higher in OLETF than in LETO8. We postulated that a beneficial 
effect of canagliflozin on DM-induced worsening of CRS, if any, 
should be detectable in OLETF. 
 
MATERIALS AND METHODS 
This study was approved by the Animal Use Committee of Sapporo 
Medical University (16-060_17-055). 
 
Animals and experimental protocol 
Administration of canagliflozin and induction of MI: Protocol 1 
Male LETO and OLETF (Sankyo Lab Service, Tokyo, Japan) at the 
ages of 25-30 weeks were used in all experiments. Rats were 
subcutaneously pretreated with a vehicle (dimethyl sulfoxide and 
polyethylene glycol; 1:1 vol:vol) or canagliflozin (1 mg/kg per day) 
for 2 weeks using osmotic minipumps (Alzet, Cupertino, CA).  
After measurement of blood pressure and pulse rate by a tail-cuff 
method, rats were prepared for induction of MI or a sham operation 
as in our previous studies8,20,23. In brief, the rats were anesthetized 
with isoflurane (1-2%) and a marginal branch of the left coronary 
artery was permanently ligated to induce MI. All rats were allowed 
ad-lib access to water but were restricted from food for 12 hr after 
surgery. The rats were divided into 6 groups: LETO-sham, LETO-
MI, OLETF-sham, OLETF-MI, canagliflozin-treated OLETF-sham 
and canagliflozin-treated OLETF-MI groups. 
Protocol 2: 
In this protocol, the effect of fasting on renal susceptibility to CRS 
in canagliflozin-treated OLETF was examined. OLETF treated with 
the vehicle or canagliflozin were fasted for 12 hr and then the 
coronary artery of each rat was permanently ligated. 
Sampling of blood and kidney tissues was performed at 12 hr 
after MI because our previous studies20,23 showed that 
approximately two thirds of OLETF died during a period of 48 h 
after MI. After measurements of blood pressure and heart rate 
under anesthesia, blood samples were taken via a catheter placed 
in the carotid artery. Then the kidneys were excised, and one 
kidney was quickly frozen in liquid nitrogen and stored at -80°C 
and the other kidney was fixed with 10% formaldehyde for histology. 
Blood levels of glucose, βOHB and angiotensin II were 
measured using a Glutest-mint (Sanwa Kagaku Kenkyusho, 
Nagoya, Japan), Presicion Xceed (Abbot, Chicago, IL) and 
Angiotensin II EIA Kit (Sigma-Aldrich, St. Louis, MO), respectively. 
 
Histological analyses 
Formaldehyde-fixed paraffin sections (3 μm) were stained using 
primary antibodies against neutrophil gelatinase-associated 
lipocalin (NGAL, Santa Cruz Biotechnology (sc-50531), 1:100) and 
kidney injury molecule-1 (KIM-1, R&D Systems (AF3689), 1:20).  
The NGAL- and KIM-1-positive areas were determined in 10 
randomly selected fields from 6 kidneys in each group. The 
glomerular area was excluded for analyses of NGAL and KIM-1. 
 
Cell culture and treatment 
NRK-52E cells, a rat renal proximal tubular cell line, were cultured 
with Dulbecco’s modified Eagle’s medium containing 10% bovine 
serum. After serum deprivation for 24 hr, cells were pretreated with 
βOHB (Sigma-Aldrich) for 1 hr followed by 24 hr-incubation with 3 
μM of angiotensin II (Alomone Labs, Jerusalem, Israel). After 24 hr, 
cells were harvested for immunoblotting. 
 
mRNA quantification 
Total RNA was isolated from frozen tissues by using an RNeasy 
Fibrous Tissue Mini Kit (Qiagen, Valencia, CA, USA).  First-strand 
cDNA was synthesized using a SuperScript VILO™ cDNA 
Synthesis Kit (Life Technologies). DNA amplification was 
performed in ABI PRISM7500 (Life Technologies) by using 
Taqman Universal PCR Master Mix. Taqman gene expression 
assays are shown in the Supplemental table 1. All assays were 
performed in duplicate and by the standard curve method using 
serial cDNA dilution. β-actin served as an internal control. 
 
Immunoblotting 
Immunoblot analysis was performed as in our previous 
studies8,20,22. Equal amounts of protein were analyzed by 
immunoblot assays using specific antibodies (Supplemental Table 
1). 
Values are mean ± SEM. *P<0.05 vs. LETO, †P<0.05 vs. OLETF, ‡P<0.05 vs. OLETF with fasting. 
Table. 1.  Physiological parameters before induction of myocardial infarction. 
Protocol 1 (without fasting before surgery)
Body weight Blood glucose β-hydroxubutyrate Heart rate Mean blood pressure
(g) (mg/dL) (mmol/L) (bpm) (mmHg)
LETO 21 578 ± 15 139 ± 4 0.42 ± 0.03 337 ± 5 114 ± 2
OLETF 21 646 ± 10* 343 ± 28* 0.35 ± 0.03 343 ± 4 119 ± 1*
OLETF+canagliflozin 23 640 ± 8* 184 ± 9† 0.39 ± 0.02 350 ± 2 119 ± 1*
Protocol 2 (Fasted before myocardial infarction)
OLETF 10 622 ± 10 164 ± 17 0.54 ± 0.05 337 ± 9 110 ± 4




Measurements of lipid peroxidation and xanthine oxidase 
activity 
Levels of malondialdehyde (MDA) and 4-hydroxynonenal (4HNE), 
indicators of lipid peroxidation, and xanthine oxidase activity in 
renal tissues were measured using a Lipid Peroxidation Microplate 
Assay Kit (Oxford Biomedical Research, Oxford, MI, FR12) and a 




Data are presented as means ± SEM. One-way ANOVA and 
Student-Newman-Keuls post hoc test were used to analyze 
differences in data among multiple groups. Unpaired Student’s 
two-tailed t-test was used to determine statistical significance of 
two data sets. Differences in mortalities in treatment groups were 
examined by the chi-square test. For all tests, a difference was 
considered to be statistically significant if p was less than 0.05. All 




Mortality after MI 
In Protocol 1, none of sham-operated rats in the LETO (n= 10), 
OLETF (n= 10) or canagliflozin-treated OLETF groups (n= 10) died 
after surgery. On the other hand, approximately 30% of the rats 
died within 12 hr after MI: 3 of 14 rats in the LETO-MI, 5 of 16 rats 
in the OLETF-MI and 6 of 19 rats in the canagliflozin-treated 
OLETF-MI groups. In protocol 2, 5 of 15 rats in the OLETF-MI and 
5 of 14 rats in the canagliflozin-treated OLETF-MI groups died 
within 12 hr after MI, suggesting that a fasting condition did not 
influence the mortality rate in OLETF. Mortality rates did not differ 
in the study groups with MI. 
 
Metabolic and hemodynamic profiles 
OLETF had larger body weight and higher casual blood glucose 
level than those of LETO, and treatment with canagliflozin reduced 
the blood glucose level without affecting body weight in OLETF 
(Table 1). Blood βOHB levels were similar in LETO, OLETF and 
canagliflozin-treated OLETF when blood was sampled without 
fasting. Mean blood pressure, but not heart rate, in a conscious 
state was higher by ~5 mmHg in OLETF than in LETO, and 
canagliflozin did not change these parameters. In Protocol 2, 12 hr 
of fasting reduced blood glucose levels in OLETF, and there was 
no statistical difference between glucose levels in OLETF and 
canagliflozin-treated OLETF. However, blood βOHB level was 
significantly elevated after 12 hr of fasting in canagliflozin-treated 
OLETF. 
At 12 hr after the operation (and fasting), blood glucose levels 
were still higher in OLETF than in LETO and treatment with 
canagliflozin significantly reduced the blood glucose level in 
OLETF (Table 2). The level of βOHB after MI was slightly increased 
in OLETF and markedly increased in canagliflozin-treated OLETF. 
Although blood urea nitrogen levels were comparable in the sham-
operated LETO and OLETF, serum creatinine level was lower in 
OLETF than in LETO, reflecting glomerular hyperfiltration 
associated with diabetes in this model8,22,24. MI did not affect these 
indices of glomerular function in either LETO or OLETF. 
Canagliflozin treatment increased blood urea nitrogen level but not 
serum creatinine level after MI. Serum angiotensin II level after MI 
was similar in LETO and OLETF and canagliflozin treatment with 
or without fasting did not change the angiotensin II level in OLETF. 
Acidemia was not induced by canagliflozin even after MI and 12 hr 
of fasting. After anesthesia, heart rate was lower in OLETF than in 
LETO regardless of induction of MI and canagliflozin treatment, 
though mean blood pressures were comparable among the six 
groups. In Protocol 2, continuation of fasting for 24 hr reduced 
blood glucose level and increased βOHB level in canagliflozin-
treated OLETF. Other parameters were not significantly affected 
by longer fasting (Table 2). 
 
Acute kidney injury after MI in OLETF 
As in our previous study8, PAS staining in kidney sections did not 
show detectable abnormalities in tubular cells, such as loss of the 
brush border, tubular dilation, cast formation and cell lysis, in LETO 
and OLETF regardless of MI, though sizes of glomeruli were larger 
Table. 2.  Blood analyses and hemodynamic parameters 12 hr after surgery 
Values are mean ± SEM. MI, myocardial infarction. *P<0.05 vs. LETO-Sham, †P<0.05 vs. LETO-MI, ‡P<0.05 vs. OLETF-Sham, §P<0.05 vs. OLETF-MI, 
¶P<0.05 vs. corresponding sham-operated rats, **P<0.05 vs. OLETF with fasting, Measurement of angiotensin II was carried out from 7-8 samples. 
Protocol 1 (without fasting before surgery)
Blood glucose β-hydroxubutyrate Blood urea nitrogen  Serum creatinine Angiotensin II Arterial pH Heart rate Mean blood
pressure
N (mg/dL) (mmol/L)  (mg/dl)  (mg/dl)  (pg/ml) (bpm) (mmHg)
Sham 10 129 ± 4 0.54 ± 0.05 15.6 ± 0.9 0.49 ± 0.02  7.431 ± 0.013 350 ± 18 92 ± 4
MI 11 137 ± 8 0.60 ± 0.06 19.0 ± 1.5 0.48 ± 0.03 50.5 ± 19.1 7.412 ± 0.012 384 ± 14 84 ± 5
Sham 10 196 ± 26 0.31 ± 0.04 15.6 ± 0.7 0.35 ± 0.01*  7.426 ± 0.016  280 ± 12* 79 ± 5
MI 11 249 ± 23†‖ 1.09 ± 0.08 20.7 ± 1.2 0.39 ± 0.03† 36.9 ± 9.9 7.401 ± 0.008  295 ± 10† 87 ± 3
Sham 10 130 ± 9‡ 0.70 ± 0.05 17.2 ± 1.0 0.35 ± 0.02*  7.395 ± 0.008 264 ± 7* 80 ± 4
MI 13 176 ± 15§        4.56 ± 0.45†§¶       31.8 ± 1.7†§¶ 0.39 ± 0.02† 86.1 ± 20.2 7.377 ± 0.014     316 ± 8†¶ 79 ± 4
Protocol 2 (Fasted before myocardial infarction)
OLETF MI 10 166 ± 15 1.37 ± 0.17 19.4 ± 0.7 0.40 ± 0.02 87.2 ± 37.0 7.409 ± 0.017 317 ± 11 85 ± 4
OLETF+
Canagliflozin






in OLETF (data not shown). 
In Protocol 1, NGAL signals in immunohistochemistry were 
barely detected in LETO regardless of MI (Figure 1A, C). The 
extent of NGAL staining of renal tubules in sham-operated OLETF 
was not significantly different from that in LETO. However, OLETF 
with MI showed focal NGAL-positive areas in tubular epithelial cells, 
and the NGAL-positive area was significantly larger than that in 
sham-operated OLETF (Figure 1A, C). Treatment with 
canagliflozin without fasting did not change the NGAL staining in 
OLETF. NGAL mRNA level in the kidney was higher in sham-
operated OLETF than in sham-operated LETO (Figure 1D). The 
expression level of NGAL was not affected by canagliflozin 
treatment. In Protocol 2, although fasting alone did not reduce 
NGAL levels, the extent of the NGAL-positive areas and the level 
of NGAL mRNA after MI in OLETF were both significantly 
decreased in canagliflozin-treated OLETF (Figure 1B-D). 
Immunohistochemical staining of KIM-1 revealed few KIM-1 
signals in LETO regardless of MI in Protocol 1 (Figure 2A). KIM-1-
positive cells were detected mostly as proximal tubular epithelial 
cells in OLETF, and the extent of KIM-1-positive areas was 
increased in sham-operated OLETF compared to that in LETO and 
was further increased after MI. The extent of KIM-1-positive areas 
in OLETF was not affected by treatment with canagliflozin (Figure 
2A, C). In Protocol 2, however, canagliflozin with pre-MI fasting 
decreased the extent of the KIM-1-positive area after MI in OLETF 
(Figure 2B, C). The expression pattern of KIM-1 mRNA was similar 
to that of KIM-1 staining (Figure 2D). 
 
Involvement of renal TLR activation, RAA system and AMPK 
activation 
Since we recently found involvement of TLR activation in CRS in 
OLETF8, we assessed changes in TLR-mediated signaling after MI 
by canagliflozin. Expression levels of TLR2, TLR4, IL-6, IL-1β and 
CCL3 were higher in OLETF than in LETO, though most of the 
differences did not reach statistical significance (Figure 3). 
Treatment with canagliflozin significantly reduced the mRNA level 
of TLR4 but not those of TLR2 or cytokines and chemokines. The 
mRNA levels of these molecules involved in TLR-mediated 
signaling were comparable in OLETF and canagliflozin-treated 






























































































Figure 1. Analysis of NGAL expression in the kidney after myocardial infarction. 
(A and B) Representative images of immunohistochemistry for neutrophil gelatinase-associated lipocalin (NGAL) in kidney sections from LETO and OLETF 
treated with a vehicle (Veh) or canagliflozin (Cana) for 2 weeks that were sampled 12 hr after a sham operation (Sham) or myocardial infarction (MI) without 
fasting (protocol 1, A) and with fasting (protocol 2, B) before surgery. (C) Summary data of NGAL-positive areas. In each group, 10 randomly selected fields 
from 9~13 kidneys were analyzed. (D) Quantification of NGAL mRNA levels in the kidney. N=8~12 in each group. *P<0.05. 
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Renal mRNA level of TGF-β was higher in OLETF than LETO 
after MI, suggesting that renal RAA activity was increased in DM 
rats. However, the increased renal TGF-β mRNA level in OLETF 
was not altered by canagliflozin treatment with or without fasting 
(Figure 3B). In contrast, levels of TGF-β mRNA in the non-infarcted 
myocardium after MI were similar in LETO and OLETF (data not 
shown). 
Phosphorylation level of AMPKα at Thr172 in the kidney at 12 hr 
after MI was unchanged in OLETF compared with that in LETO. 
The level of phospho-AMPK was increased in canagliflozin-treated 
OLETF, though there was no further increase in phospho-AMPK 
level by fasting in canagliflozin-treated OLETF (Figure 4B). 
 
Oxidant stress and its regulatory proteins in the kidney 
The level of MDA+4HNE in the kidney after MI was higher in 
OLETF than in LETO, and this increase in OLETF was blocked by 
canagliflozin only when rats were fasted for 12 hr before induction 
of MI (Figure 5A). 
Xanthine oxidase activity was significantly increased in OLETF 
compared to that in LETO after MI. This higher activity in OLETF 
was not modified by canagliflozin regardless of fasting (Figure 5B). 
Protein levels of both NADPH oxidase (NOX) 2 and NOX4 were 
significantly increased in OLETF compared to those in LETO. 
These increases in NOX2 and NOX4 proteins were significantly 
suppressed by canagliflozin only when rats were fasted for 12 hr 
before MI (Figure 5C, D). The mRNA levels of NOX2 and NOX4 
were higher in OLETF than in LETO, and the increased expression 
levels were also reduced by canagliflozin with fasting (Figure 5E, 
F). 
As shown in Figure 4, protein levels of Mn-SOD, catalase and 
SIRT3, a mitochondrial sirtuin, in the kidney after MI were similar 
in OLETF and LETO, and canagliflozin treatment did not change 
these levels in OLETF. 
 
Effects of exogenous βOHB on NOX4 induction 
Angiotensin II (3 μM) increased protein levels of NOX4. Pre-
incubation of 1 and 2 mM of βOHB attenuated the increase in 
NOX4 proteins by 50% and 62%, respectively (Figure 6). 
Figure 2. Analysis of KIM-1 expression in the kidney after myocardial infarction. 
(A and B) Representative images of immunohistochemistry for kidney injury molecule-1 (KIM-1) in kidney sections from LETO and OLETF pretreated with a 
vehicle (Veh) or canagliflozin (Cana) 12 hr after a sham operation (Sham) or myocardial infarction (MI) without fasting (A) and with fasting (B) before surgery. 
(C) Summary data of KIM-1-positive areas. In each group, 10 randomly selected fields from 9~12 kidneys were analyzed. (D) Quantification of KIM-1 mRNA 

































































































As in our previous studies8,22, OLETF at the ages of 25-30 week 
showed phenotypes of an early stage of diabetic nephropathy: 
lower serum creatinine level, indicating glomerular hyperfiltration 
(Table 2), no histological abnormalities in the kidney except for 
larger sizes of glomeruli, and higher level of KIM-1 protein without 
change in NGAL level (Figures 1 and 2) compared with those in 
LETO. After acute MI, protein levels of NGAL and KIM-1 in the 
kidney were significantly increased by 3.2-fold and by 1.6-fold, 
respectively, in OLETF, though blood urea nitrogen and serum 
creatinine levels were not changed. The impact of MI on the kidney 
appears modest, and unchanged level of serum creatinine 
indicates that renal injury in OLETF after MI is a model of 
“subclinical AKI” in patients with CRS. Subclinical AKI is not a trivial 
injury since it has a significant impact on clinical outcomes25,26. 
Haase et al. demonstrated that subclinical AKI, defined as elevated 
urine or plasma NGAL level without elevation of serum creatinine 
level, increases the risk of adverse outcomes, including death and 
renal replacement therapy, by 3.6-fold25. The findings support the 
notion that the present model of MI-induced AKI is a clinically 
relevant model of type 1 CRS. 
Compared with the findings in a previous study using the same 
animal model of DM8, differences in the expression levels of TLRs 
and inflammatory cytokines after MI between OLETF and LETO 
were slightly smaller in the present study. The reason for the 
difference is unclear, but the possible difference in sizes of MI 
might have been involved, since amount of damage-associated 
molecular patterns released from the infarcted myocardium 
depends on the size of MI27. Mean blood pressure drop after MI in 
Figure 3. Expression levels of toll-like receptors, cytokines, and chemokines in the kidney. 
Expression levels of genes related to toll-like receptors (A) and cytokines and chemokines (B) in the kidney. N=6-11 in each group. *P<0.05. 











































































































































































































































































































































































































OLETF was larger in our previous study (64 mmHg in the MI group 
vs. 78 mmHg in the sham group)8 than in the present study (87 
mmHg in the MI group vs. 79 mmHg in the sham group, Table 2), 
suggesting that the extent of ventricular damage after MI was 
smaller in the present study. 
In addition to activation of TLR-mediated signaling, increased 
oxidative stress and RAA system contributes to type 1 CRS2,3,28. 
NOX4 is highly expressed in renal tubules, renal fibroblasts, 
glomerular mesangial cells and podocytes, and upregulation of 
NOXs together with increased generation of reactive oxygen 
species (ROS) has been reported in the diabetic kidney29,30. 
Inhibition of NOX4 in experimental models of DM afforded marked 
protection from both structural and functional kidney damage31,32. 
Contribution of xanthine oxidase to ROS-mediated renal injury in 
Figure 4. Effects of canagliflozin and fasting on expression levels of BNP, AMPK and anti-oxidant proteins. 
Representative immunoblots (left) and summary data (right) of protein levels are shown. Protein level for BNP in the non-infarct myocardium (A) and protein 
levels for phospho-AMPKα at Thr172 (B), Mn-SOD (C), catalase (D) and SIRT3 (E) in the kidney. Samples were run on the same gel but were not contiguous. 









































































































































































































DM has also been indicated by the findings that inhibition of 
xanthine oxidase activity significantly suppressed kidney injury in 
DM33,34. In the present study, renal expression levels of 
MDA+4HNE, NOX2 and NOX4 and xanthine oxidase activity were 
significantly higher in OLETF than in LETO (Figure 5). Since renal 
TGF-β mRNA level was higher in OLETF than in LETO (Figure 3B), 
the increases in NOXs in OLETF may be partly explained by 
activation of renal RAA system35. Canagliflozin significantly 
Figure 5. Effects of canagliflozin and fasting on oxidative stress in the kidney after myocardial infarction. 
(A) Malondialdehyde (MDA) + 4-hydroxynonenal (4HNE) levels in the kidney. Kidney tissues were sampled 12 hr after MI in LETO, OLETF, and canagliflozin 
(Cana) -treated OLETF. Vehicle (Veh) - or canagliflozin-treated OLETF with 12 hr fasting before MI were also analyzed. N=5-6 in each group. (B) Xanthine 
oxidase activity in the kidney. N=6 in each group. (C) Representative immunoblots for NOX2 (left) and summary data of NOX2 protein level normalized by β-
actin level (right) in the kidney. N=6 in each group. (D) Representative immunoblots for NOX4 (left) and summary data of NOX4 protein level normalized by β-
actin level (right) in the kidney. N=6 in each group. In (C) and (D), samples were run on the same gel but were not contiguous. (E and F) Levels of NOX2 (E) 




















































































































































































































































reduced levels of NOX2 and NOX4 but not xanthine oxidase 
activity (Figure 5), while canagliflozin did not significantly change 
TGF-β mRNA level. Renal activity of RAA system after an SGLT2 
inhibitor was reported to be increased, decreased or unchanged 
depending on the reports36-38. The differences in study subjects, 
duration of SGLT2 inhibitor treatment or volume change after the 
treatment might explain the inconsistent results of the previous 
reports and the present study. Nevertheless, the findings suggest 
that NOX-mediated oxidative stress plays a major role in AKI in 
OLETF and is a target of canagliflozin treatment. 
Of interest, protection against AKI by canagliflozin was detected 
only when the rats were fasted before induction of MI. Protective 
effects of canagliflozin on tissue MDA+4HNA and on NOX2 and 
NOX4 proteins were also observed when combined with fasting 
before MI (Figure 5A, C-F). Hemodynamic parameters, including 
blood pressure and heart rate, before and 12 hr after MI were 
comparable in canagliflozin-treated OLETF with or without fasting 
(Tables 1 and 2). On the other hand, blood βOHB level was 2-fold 
higher in canagliflozin-treated OLETF with pre-MI fasting than in 
canagliflozin-treated OLETF without fasting (0.79±0.06 vs. 
0.39±0.02 mmol/L) (Table 1), whereas blood βOHB levels after MI 
were increased to 3~4 mmol/L in canagliflozin-treated OLETF 
regardless of pre-MI fasting (Table 2). As shown in Figure 7, the 
level of renal NGAL expression was inversely correlated with blood 
βOHB levels before MI but not with those at 12 hr after MI, 
suggesting a significant association of increase in βOHB before MI 
and renal protection from CRS by canagliflozin. 
Since the correlation between blood βOHB and renal NGAL 
expression was modest (r=-0.41), mechanisms other than 
increased βOHB is possibly involved in renoprotection by 
canagliflozin with pre-MI fasting. Activation of AMPK is one of 
candidates22, 39-41 but the present results showed the contribution 
of AMPK to renoprotection against DM-induced worsening of CRS 
was limited. It has been suggested that reduction of oxygen 
consumption in the proximal tubules and prevention of cellular 
senescence are the mechanisms of renoprotection by an SGLT2 
inhibitor42-45, but whether these mechanisms are involved in 
amelioration of CRS should be examined in future studies. 
Since it is actually difficult to maintain blood βOHB level by 
administration of exogenous βOHB to a level achieved by SGLT2 
inhibitor treatment and fasting in OLETF46, we examined the 
effects of βOHB on NOX4 protein level in vitro. Pre-incubation with 
βOHB attenuated angiotensin II-induced upregulation of NOX4 
protein expression in NRK-52E cells (Figure 6). Recently, it was 
reported that βOHB functions as an endogenous HDACs inhibitor 
and suppresses oxidative stress by upregulation of anti-oxidative 
proteins, including Mn-SOD and catalase, in the kidney17. Kong et 
al. reported that exposure of PC12 cells to βOHB attenuated H2O2-
induced upregulation of NOX2 and NOX4 proteins47. They also 
showed that knockdown of either HDAC1 or HDAC2 reduced 
NOX2 and NO4 protein levels47. Taken together, the findings 
suggest that elevation of blood βOHB level before MI is causally 
related to suppressed expression of NOXs and oxidant stress in 
the kidney after MI in canagliflozin-treated OLETF with pre-MI 
fasting. Interestingly, in contrast to suppressed expression of 
NOXs, up-regulation of anti-oxidative stress proteins was not 
accompanied by elevation of blood βOHB level by canagliflozin 
and fasting. These results suggest that increased βOHB by 
canagliflozin treatment protected the kidney from injury 
downstream of RAA pathway but independent from HDAC pathway. 
Precise mechanisms how βOHB attenuate NOXs protein and 
subsequent renal injury are uncertain and warrant further 
Figure 6. Effects of exogenous βOHB on NOX4 protein in vitro 
Representative immunoblots (left) and summary data (right) of NOX4 protein 
level normalized by vinculin are shown. (A) NRK-52E cells were treated with 
angiotensin II (Ang II) in the presence or absence of βOHB. (B) NRK-52E 
cells were treated with vehicle or βOHB. N=6 in each treatment. *P<0.05. 
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Figure 7. Correlation between blood β-hydroxybutyrate levels and 
NGAL-positive areas in OLETF after myocardial infarction. 
Relationship between blood β-hydroxybutyrate (βOHB) levels before (A) or 
12 hr after (B) induction of myocardial infarction (MI) and neutrophil 
gelatinase-associated lipocalin (NGAL) -positive areas in OLETF (closed 
circle), canagliflozin (Cana) -treated OLETF (open circle), OLETF with 12 hr 
of fasting before MI (closed triangle), and Cana-treated OLETF with fasting 
(open triangle). 
























































Several reports have shown that treatment with an SGLT2 
inhibitor ameliorated diabetic nephropathy by suppression of 
NOX4 expression and subsequent oxidative stress in DM 
mice12,48,49. Thus, the reason why treatment with canagliflozin 
without fasting failed to suppress NOX4 expression and oxidative 
stress in the present study is uncertain. However, there are a few 
possible explanations. First, the duration of SGLT2 inhibitor 
treatment was shorter in this study than in earlier studies (2 weeks 
vs. 8-12 weeks), which possibly resulted in a lower level of blood 
ketone bodies16,50. In fact, blood βOHB level after 12 hr fasting was 
larger after 8 weeks of canagliflozin treatment than that of 2 weeks 
of treatment (1.08±0.12 vs. 0.79±0.06 mmol/L, p<0.05). Second, 
since OLETF are hyperphagic due to a lack of cholecystokinin-A 
receptor in the brain19, time periods of fasting may be shorter in 
OLETF under the condition of ad libitum feeding, leading to less 
elevation of blood ketone level, compared with those in db/db and 
Akita mice. In a clinical setting, chronic treatment with an SGLT2 
inhibitor increased blood ketone level throughout the day in 
patients with DM16,51. Therefore, βOHB-mediated renoprotection 
would be appeared in DM patients treated with an SGLT2 inhibitor, 
but the protection might be attenuated after meal. 
There are limitations in the present study. First, AKI was 
assessed only at 12 hr after MI, and the time courses of AKI after 
MI and impact of AKI on the long-term function of diabetic kidneys 
were not examined. The high mortality rate (i.e., approximately 
60%) of OLETF within 48 h after MI precludes tissue sampling at 
later time points after MI in OLETF without selection bias in 
data20,23. Second, treatment with canagliflozin may have affected 
cardiac function after MI, since SGLT2 inhibitors reportedly 
reduced heart failure in clinical and experimental studies52,53. 
However, it is unlikely that canagliflozin had a large impact on the 
cardiac function 12 hr after MI, since myocardial BNP levels 
(Figure 4A) and mortality rates after MI were not different in 
canagliflozin-treated and -untreated OLETF. 
In conclusion, the results of the present study suggest that 
increased susceptibility to MI-induced AKI in DM rats is mediated 
by a NOX-induced increase in oxidative stress in the kidney and is 
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Antibodies Source Cat. No.
Rabbit monoclonal anti-NOX2 Abcam ab129068
Rabbit monoclonal anti-NOX4 Abcam ab133303
Rabbit polyclonal anti-Mn-SOD2 Merck Millipore 06-984
Mouse monoclonal anti-catalase Sigma-Aldrich C0979
Rabbit monoclonal anti-Sirt3 Cell Signaling Technology #5490
Rabbit monoclonal anti-phospho-AMPKα (Thr172) Cell Signaling Technology #2535
Rabbit polyclonal anti-AMPKα Cell Signaling Technology #2532
Rabbit polyclonal anti-BNP Abcam ab19645
Goat polyclonal anti-GAPDH Santa Cruz sc-20357
Mouse monoclonal anti-β actin Sigma-Aldrich A5316
Mouse monoclonal anti-vinculin Sigma-Aldrich V9131















Supplemental Table 1.  Antibodies and Taqman gene expression assays
